Sector News

Medtronic announces restructuring to trim costs by billions

January 10, 2018
Life sciences

Medical-device giant Medtronic announced a multibillion-dollar restructuring program Monday that will impact an undisclosed number of employees.

The company discussed its plan at the J.P. Morgan Healthcare Conference on Monday and unveiled some details in a Securities and Exchange Commission filing. Medtronic expects the plan to result in more than $3 billion in annual gross savings by the end of its 2022 fiscal year.

The restructuring will affect an undisclosed number of employees, but Medtronic’s total employee count will hold steady, the company said in an SEC filing. Medtronic has about 9,000 employees in Minnesota and is among the state’s largest employers.

“The company expects that its overall employee base will remain relatively unchanged, as new jobs are created in new capability areas and resources are deployed to support the company’s growing market needs,” Medtronic said in a regulatory filing.

Medtronic expects to record charges of between $1.6 billion and $1.8 billion over a five-year period as a result of the restructuring, which it named “Enterprise Excellence Program.” Between 40 and 50 percent of those charges will be tied to employee-related costs, including severance expenses.

Medtronic cut an undisclosed number of jobs at its operations in Memphis over the summer, and said in August it would lay off 185 workers in Illinois after closing a distribution center. A company spokesman told MassDevice that Medtronic has more than 4,000 open positions.

Medtronic unveiled some of the program’s goals — such as improving productivity and integrating manufacturing systems — but few details.

“The program is designed to drive operating margin improvement as well as fund investment in strategic growth initiatives,” the company said in the regulatory filing.

Dublin-based Medtronic’s operational headquarters in Fridley.

By Katharine Grayson

Source: Biz Journal Minneapolis

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach